Chek the Channels
Meet 125 Mgmt Teams
Data and Additional Partnerships to Expand Further Value
Dyadic International Inc. is a biotechnology company developing a proprietary C1 expression platform to express and manufacture biologic products. The C1 technology is part of a fungi expression system, which utilizes inexpensive substrates yielding a high level of production. Dyadic is currently improving and optimizing the production of biological products in a C1 expression system.
Ahu Demir, Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to full report for price target, fundamental analysis and rating.
- Progressing Towards Validation of Technology. We continue to believe that the major inflection point for DYAI shares is further validation of C1 technology in biologic manufacturing, data expected by year-end 2019. This will also open doors for additional partnership opportunities.
- Second Quarter Earning Update. On August 13, the company reported $0.4 million in revenues, $0.7 million in R&D expenses and $1.4 million in G&A expenses. Net loss was $2.2 million, or ($0.08) per share. The reported numbers are in line with...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.